Effects of rhCC10 as a Post-Treatment in Mice Challenged with Phosgene
Technical rept. May-Nov 2002
ARMY MEDICAL RESEARCH INST OF CHEMICAL DEFENSE ABERDEEN PROVING GROUND MD
Pagination or Media Count:
In this study we evaluated the therapeutic efficacy of a post-exposure administration of rhCC10 Claragen, Inc., Rockville, MD against a toxic concentration of phosgene. rhCC10 0 is described as a 1 10kDa Clara Cell protein, an anti-inflammatory lung protein that is present on all mammalian mucosal surfaces. It protects against infection and environmental pollutants but apparently not against phosgene, which has a substantial effect in bronchioles and permeability in the deep alveolar lung. Supplementation with rhCC10 did not increase survival of animals exposed to phosgene compared with those treated with saline alone. In addition, the results of the bioassays show no significant differences between saline and the rhCC10 doses therefore, there has not been any determination of rhCC10 as a beneficial post-exposure therapy for phosgene.
- Chemical, Biological and Radiological Warfare